Market Pulse News Alert for this AM, Stocks to Watch are:
Revolutions Medical Corporation (OTCBB: RMCP), SIRIUS XM Radio Inc.
(NASDAQ: SIRI), Medical Connections Inc. (OTCBB: MCTH) and BSD
Medical Corp. (NASDAQ: BSDM).
Investors need to be watching Revolutions Medical Corporation
(OTCBB: RMCP) this AM! Revolutions Medical Corporation (RevMed) is
engaged in the design, development, commercialization and
acquisition of new products and tools to make healthcare safer and
less expensive. RevMed's products include safety-engineered medical
devices (SEMDs) and the flagship RevVac safety syringe (FDA
Approved), safety blood drawing devices, and safety IV catheters.
The products use a proprietary patented technology in which a
vacuum causes the needle to retract into the barrel of the syringe
or device after an injection is administered or blood is drawn.
RevMed owns the patents to manufacture the disposable retractable
syringe and phlebotomy device. The world market for SEMDs is
projected to exceed $2 billion this year and is forecasted to
maintain a 20% annual growth rate in the near term. RevMed also
offers RevColor, RevDisplay and Rev3D, software solutions and
proprietary tools that are compatible with standard MRIs and
standard PACS. The software includes sorting of images, color, 3D,
and automatic segmentation of images. These tools will enhance the
physician's diagnostic confidence in an industry that is growing at
10% - 15% (more than 25 million procedures) per year with a
worldwide market potential for these tools that exceeds $3.5
billion. The company is continually looking for new and improved
technology through internal product development and acquisition.
The company's future growth will be powered by new product line
introductions, and the material expansion of existing successful
lines. RevMed's Breast Biopsy System (BBS), stereotactic (minimally
invasive) image-based localization technology, is one of those
product lines pursuing the $9.5 billion breast screening industry.
RevMed's Breast Biopsy System, the MRI enhancement software and the
SEMDs will be launching in the next 18 months. All three markets
are immediately addressable and total more than $14 billion. RevMed
recently introduced its proprietary suite of MRI software products
at the Radiology Society of North America annual meeting with great
success. Radiologists and universities world-wide received
presentations at the RMCP booth. A number of these contacts could
play an important role in the company's ongoing efforts to
clinically validate specific applications of its MRI tools prior to
the 2010 commercial launch. Never has health care been a hotter
issue, and the focus of the conversation is on increased safety at
dramatically reduced cost. Revolutions Medical has the formula for
success, and one that has them immediately positioned for a high
growth future. With 3 recurring revenue business lines with blended
gross margins projected to exceed 50% and anticipated profitability
in its first full year of operations, Revolutions Medical
Corporation is poised to become a significant player in the
healthcare and medical devices industry! RMCP just had excellent
news out in a press release before today's opening bell announcing
a recap of important milestones achieved in 2009 and offered a very
optimistic corporate outlook for 2010! Investors should be watching
this one closely!
Revolutions Medical Corporation (OTCBB: RMCP), producers of the
RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI
Technology, today provided a recap of important milestones achieved
in 2009 and offered a corporate outlook for 2010 through the
following open letter to shareholders:
From the Desk of RevMed CEO Ron Wheet
Dear RevMed Shareholders,
This last year was truly a watershed one for RevMed, and it has
brought us a great distance towards the commercial launch of the
RevVac safety syringe, and the subsequent launch of our
revolutionary suite of color MRI software. Consistent with our
commitment to proactive investor communication, we would like to
recap the past year and provide a brief outlook for 2010.
Fiscal Year 2009
This last year saw horrific market conditions, a plague of
business failures and consumers everywhere tightening their belts.
Yet the medical industry continued to expand. Revolutions Medical
not only weathered the storm but was successful in raising capital
and meeting its short term operational objectives. We reached the
tipping point of launching our two core recurring revenue business
lines. We believe we have laid the foundation in 2009 to achieve
profitability in our first full year of distribution and sales; we
began the transition from a company developing products to one
manufacturing and distributing potential market game-changers, and
to a company poised to generate real revenue and earnings.
Looking briefly to 2008 and continuing through 2009 we have
achieved the following:
-- Ascended to the Over-the-Counter Bulletin Board and acquired 100% of
Clear Image Acquisition Corporation, the developer of our MRI software
technology
-- To date, approximately $3 MM has been invested toward RevColor and
Rev 3D MRI product development
-- To date, approximately $3 MM has been invested toward the RevVac
Safety Syringe product development
-- Received FDA 510K clearance for the RevVac safety syringe
-- Launched the initial steps of RevVac manufacturing process for the
3ml safety syringe
-- Forged a distribution partnership with Libra International in South
America -- the first of many targeted worldwide syringe markets
-- Began cultivating relationships with more than 50 distributors
worldwide and now will initiate the process of signing distribution
agreements with those that fit our criteria to distribute our products
-- Introduced the MRI suite of products on the imaging technology and
software world stage at the Radiological Society of North America
(RSNA) in Chicago
-- Signed RevMed President Tom O'Brien, acclaimed pioneer in MRI
sales/marketing and the former CEO of private and public medical
companies, to a 3-year employment agreement
-- Opened our new corporate office at:
670 Marina Drive, Third Floor
Charleston, SC 29492
-- Appointed distinguished law firm Anslow & Jaclin, LLP as legal
counsel, represented by firm partner Joseph M. Lucosky, Esq.
-- Hired the accredited accounting firm Elliott Davis LLC
-- Engaged Cirrus Financial Communications as our external Investor
Relations Officer.
Fast Facts
Prior to our 2010 outlook and in response to investor inquiries,
we would like to take this opportunity to reiterate some
fundamental company information.
Capital Structure and Balance Sheet
-- Basic shares outstanding: 33.1 MM
-- Fully diluted shares outstanding: 43.2 MM
-- Approximate float: 24.0 MM shares
-- 52-week range: $0.14 - $0.71
-- No long term debt
Intellectual Property (IP)
RevMed has secured multiple design, technology and process patents,
and has filed to receive many more -- we are confident that we
enter the market substantially protected, and will only further
secure our defense against competition in the months to come. To
date, we can claim the following:
-- Image Enhancement: 4 U.S. and 2 international patent
applications filed
-- Safety Syringe: 4 U.S. patents awarded and
7 international patent applications filed
-- Blood Drawing Device: 1 U.S. patent awarded
Fiscal Year 2010
We are very optimistic about 2010, and below are some
anticipated items/initiatives of note for the coming year:
-- Sign up distributors nationally and worldwide
-- License additional syringe manufacturers
-- Integrate MRI tools into a delivery platform
-- Receive validation of MRI tools with major teaching hospitals and
experts in the various applicable fields of medicine
-- Confirm additional MRI diagnostic applications such as Alzheimer's,
concussion, cardiac disease and breast disease
-- Negotiate agreements with other equipment manufacturers and value-added
resellers
-- Set up, packaging and quality assurance in Charleston, South Carolina
-- Continue to expand family of safety syringes, blood drawing devices and
other products in aesthetics, etc
-- Continue to build management team, adding a Chief Technology Officer,
International Sales Manager and others as appropriate
In closing, we would like to thank you all for your past
support, continued interest, and in many cases, your dedication and
patience. After years of research and development, we believe our
vision will become reality in 2010. Never has health care been a
more important issue, and the focus of the conversation is on
increased safety at dramatically reduced cost. We feel that RevMed
is perfectly positioned to capitalize on this vital need through
our two immediate product line opportunities.
About Revolutions Medical Corporation
(www.revolutionsmedical.com)
RevMed's products include the RevVac safety syringe (FDA
approved), safety blood drawing device and safety IV catheter.
RevMed also provides RevColor, RevDisplay and Rev3D -- software
solutions and proprietary tools that are compatible with standard
MRIs and standard PACS. The software suite's functionality includes
sorting of images, color, 3D and automatic segmentation of
images.
Investor Resource Center
Fact Sheet:
http://content.stockpr.com/rmcp/files/RMCP_-_Fact_Sheet_09-09-09.pdf
CEO Ron Wheet Audio Interview:
http://ir.stockpr.com/revolutionsmedical/media-center/view/33/
RevVac Demo Video:
http://www.revolutionsmedical.com/videos/revac_directions_final.wmv
Stocks in the news and acting well as of late include: SIRIUS XM
Radio Inc. (NASDAQ: SIRI), Medical Connections Inc. (OTCBB: MCTH)
and BSD Medical Corp. (NASDAQ: BSDM).
Information contained herein is the opinion of Market-Pulse.com
("MP") and is intended to be used strictly for informational
purposes. You should be aware that MP attempts to assure itself of
the accuracy of the information contained in the analyses it
publishes. In this regard, MP does, at times, rely on the accuracy
of information supplied to it by the companies which are the
subject of MP's analyses and/or parties related to those companies.
MP also relies on the accuracy and integrity of information that is
contained in company press releases and reports filed with the SEC.
The companies mentioned in this publication have not approved the
content or timing of the information being published unless
otherwise noted.
MP, because it relies on information supplied by various third
parties disclaims any responsibility for the accuracy of such
information. Any investor considering making an investment in any
security which has been the subject of a MP analysis or opinion
should, before making any such investment, consult with his/her
market professional and/or do his/her own independent research
regarding the company which is the subject of an MP opinion,
recommendation or analysis. Information regarding companies which
MP has opined upon is normally available from many sources
including the subject company's filings with the SEC and various
press releases issued by the company.
You should be aware that MP is often compensated for issuing
analyses, recommendations or opinions concerning particular
companies. Its opinion is therefore not unbiased and you should
consider this factor when evaluating MP's statements regarding a
company. MP has been compensated twenty five thousand restricted
shares of Revolutions Medical Corporation by the company. MP's
officers and directors reserve the right to buy additional shares
of the companies discussed in this opinion and may profit in the
event those shares rise in value. When MP receives shares as
compensation for a profiled company, MP may sell part or all of any
such shares during the period in which MP is performing such
services. Market-Pulse.com and Market Pulse Breaking News Alert are
owned by Market Pulse LLC.
Contact: Market Pulse 800.290.8935 Email Contact
Medical Connections (GM) (USOTC:MCTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Medical Connections (GM) (USOTC:MCTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024